Klingman & Associates’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
Klingman & Associates's AZN Position: Q3 2026 in Review
Klingman & Associates reduced its AstraZeneca (AZN) stake by 0.98% in Q3 2026, selling an estimated $2.83K and leaving 1,714 shares worth $277K. The position accounts for 0.01% of the portfolio, ranked #342.
Klingman & Associates first reported a position in AZN in Q3 2025 and has held it in 5 quarters since. The position peaked at $328K in Q2 2026. 1,444 funds tracked by Wall St. Rank hold AZN as of Q3 2026.
- Klingman & Associates held 1,714 shares of AstraZeneca worth $277K as of Q3 2026.
- Klingman & Associates sold 17 AstraZeneca shares in Q3 2026, an estimated $2.83K.
- AstraZeneca made up 0.01% of Klingman & Associates's portfolio in Q3 2026, its #342 holding.
- Klingman & Associates first reported a position in AstraZeneca in Q3 2025 and has held it in 5 quarters since.
- Klingman & Associates's AstraZeneca position peaked at $328K in Q2 2026.
- 1,444 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.
Based on Klingman & Associates's 13F filing for Q3 2026, filed 20 Oct 2026.